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Abstract
Deletion of the 16p11.2 CNV affects 25 core genes and is associated with multiple symptoms affecting brain and body,
including seizures, hyperactivity, macrocephaly, and obesity. Available data suggest that most symptoms are controlled by
haploinsufficiency of two or more 16p11.2 genes. To identify interacting 16p11.2 genes, we used a pairwise partial loss of
function antisense screen for embryonic brain morphology, using the accessible zebrafish model. fam57ba, encoding a
ceramide synthase, was identified as interacting with the doc2a gene, encoding a calcium-sensitive exocytosis regulator, a ge-
netic interaction not previously described. Using genetic mutants, we demonstrated that doc2aþ/ fam57baþ/ double heterozy-
gotes show hyperactivity and increased seizure susceptibility relative to wild-type or single doc2a/ or fam57ba/ mutants.
Additionally, doc2aþ/ fam57baþ/ double heterozygotes demonstrate the increased body length and head size. Single doc2aþ/
and fam57baþ/ heterozygotes do not show a body size increase; however, fam57ba/ homozygous mutants show a strongly
increased head size and body length, suggesting a greater contribution from fam57ba to the haploinsufficient interaction be-
tween doc2a and fam57ba. The doc2aþ/ fam57baþ/ interaction has not been reported before, nor has any 16p11.2 gene previ-
ously been linked to increased body size. These findings demonstrate that one pair of 16p11.2 homologs can regulate both
brain and body phenotypes that are reflective of those in people with 16p11.2 deletion. Together, these findings suggest that
dysregulation of ceramide pathways and calcium sensitive exocytosis underlies seizures and large body size associated with
16p11.2 homologs in zebrafish. The data inform consideration of mechanisms underlying human 16p11.2 deletion symptoms.
Introduction
Identifying multigenic contribution and relevant genetic inter-
actions contributing to neurodevelopmental disorders is a huge
challenge facing the field. In these disorders, physical comorbid-
ities are frequently associated with mental health disorders and
compound challenges faced by people with these diagnoses.
Multigenic regions associated with neurodevelopmental disor-
ders include copy number variants (CNVs). Loss of one copy of
the 16p11.2 is the CNV is highly prevalent, occurring in 1 in 2000
people (1), and is linked to many symptoms affecting brain and
body function, including autism spectrum disorders (ASDs), in-
tellectual disability, developmental delay, language impair-
ment, seizures, macrocephaly, obesity, hypotonia, motor
impairment, and gastrointestinal problems (2–10).
The 16p11.2 CNV affects 25 core genes, and we considered
four models to account for the connection between loss of func-
tion in core genes and specific phenotypes or symptoms. First, a
single gene from 16p11.2 could be linked to all symptoms
(Fig. 1A). This model is not supported by the extensive sequenc-
ing analysis that has been done for people with autism and
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schizophrenia. No statistically significant variants for any of the
25 single genes from this region have been recovered (11–15),
making it unlikely that a single gene could account for all the
other associated symptoms as well. Second, two or more genes
from the 16p11.2 region interact and mediate all symptoms
(Fig. 1B). Explorations for smaller internal CNVs associated with
autism have not recovered significant hits in the 16p11.2 inter-
val (16–18), but these would not be able to account for multiple
critical genes if they are not syntenic. Third, single genes from
this region may each mediate a distinct symptom (Fig. 1C).
Extensive sequence analysis on large samples from people with
autism has not revealed statistically significant variants for any
of the 25 single genes from this region (11,12,14,15). However,
single genes have been implicated in some of the other symp-
toms associated with 16p11.2 CNVs. PRRT2 has been associated,
as heterozygous or homozygous mutations, with paroxysomal
neurological disorders, benign familial infantile seizures, febrile
convulsions, and epileptic seizures (19). A single case of epilepsy
was found in a person with a KIF22 heterozygous mutation (20).
TBX6 is a candidate for vertebral anomalies associated with
16p11.2 CNVs as hypomorphic/null compound mutations
(21,22). However, overall, there are not many single gene associ-
ations from the 16p11.2 interval, and these cannot account for
the full spectrum of symptoms associated with the CNV.
Therefore, we consider a fourth model where interaction of two
or more genes each mediates one symptom (Fig. 1D). These
could include either distinct or overlapping gene groups that in-
teract to affect each symptom. This is a complex model that has
not been addressed experimentally. There are additional mod-
els that would be composites of the third and fourth scenarios.
Animal studies have explored the relationship between
genes and phenotypes for the 16p11.2 region. Although in these
models it is difficult to assess human-specific symptoms, such
as language disorders, animal systems can give insight into evo-
lutionarily conserved phenotypes, including seizures and body
size control, which are a result of shared physiology, cell biology
and molecular biology (23–25). With regard to the ability of
single genes to mediate 16p11.2 deletion phenotypes, of eight
mouse mutants for single homologs, only one (PPP4C) had a
haploinsufficient phenotype: retarded growth (26). Some homo-
zygous mouse mutants for other 16p11.2 homologs showed
phenotypes with potential relevance to CNV deletion symp-
toms, including Doc2a/ mice, which exhibit defects in synaptic
transmission (27), and Coro1a/ and Mapk3/ mice, which
have some immune deficiencies (28,29). Other mouse studies on
16p11.2 homologs have deleted the entire syntenic interval, and
therefore do not address single gene activity (30–32). After com-
plete loss-of-function (LOF) in single genes using antisense
techniques, we previously found that 22 of 25 homologs were
active during early zebrafish development, but only two (aldoaa
and kif22) showed haploinsufficient effects on early brain mor-
phology (33). A small 16p11.2 screen in Drosophila found that a
homolog for KIF22 mediated axonal branching patterns (34).
A single study has reported that suppressing and overexpress-
ing kctd13 has reciprocal effects on head size in zebrafish, and
the suggestion was made that this reflected the opposing effects
of 16p11.2 CNV deletion and duplication on people (35). Overall,
between human genetics and animal data, there are few single
16p11.2 genes or homologs that regulate distinct symptoms
after single copy gene deletion, and only a few of the symptoms
associated with 16p11.2 CNVs can be associated with
single genes.
Based on these considerations, we explored the fourth possi-
bility outlined above (Fig. 1D), that multiple genes interact to im-
pact each 16p11.2 deletion symptom. We used the zebrafish as a
tool to address the most parsimonious hypothesis that two
16p11.2 genes interact to elicit each phenotype. We have previ-
ously noted the value of the zebrafish as a tool to study neurode-
velopmental disorders (23–25,36). Genetic manipulations are
effective, while the wide range of assays and rapid embryonic de-
velopment in zebrafish means several phenotypes can be studied
simultaneously. Although zebrafish cannot demonstrate human-
specific phenotypes associated with 16p11.2 CNVs, their genes
are orthologous to human disease genes (37). This facilitates the
discovery of the biology that triggers pathological mechanisms.
Beginning with the simplest interaction hypothesis of just two
genes involved in symptomatology, we employed an antisense
pair-wise partial LOF screen and double heterozygote lines. Our
data identify unpredicted 16p11.2 homolog interactions and new
gene functions underlying brain and body phenotypes. These
data support the hypothesis that two or more 16p11.2 genes in-
teract to mediate distinct symptoms, and identify lipid metabo-
lism and calcium-sensitive exocytosis as pivotal elements in
certain 16p11.2 deletion symptoms.
Results
A subset of interacting 16p11.2 pairs affect early brain
development and other phenotypes
We were particularly interested in genetic interactions, which
are defined as a combination of two mutations that leads to a
phenotype that cannot be predicted from the effects of either
mutation alone (38). In other words, a genetic interaction be-
tween two gene products results from a non-additive effect of
the single gene phenotypes. An additive phenotype resulting
from summation of each single gene LOF would not be consid-
ered an interaction. To test the hypothesis that two genes from
the 16p11.2 CNV interact to impact brain development, we com-
pared the effects of partial LOF in individual zebrafish 16p11.2
homologs to that of two homologs together.
Figure 1. Possible hypotheses for gene-phenotype relationships in multi-symp-
tomatic CNV disorders. (A) A single gene accounts for all of the associated symp-
toms. (B) The interaction of two or more genes accounts for all of the associated
symptoms. (C) Single genes account for a single symptom each. (D) Two or more
genes interact to affect one symptom each. These interacting genes can be in
different and overlapping sets. There are also additional models that would be
composites of the last two hypotheses.
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Unlike our previous study, where we found phenotypes as-
sociated with 70–95% single gene knockdown for the majority of
16p11.2 homologs, the partial LOF used here for interaction
analysis was50% for each gene to more closely reflect the
hemizygous state of people with 16p11.2 deletion CNVs. We de-
fined interacting gene pairs as those that gave no or little phe-
notype for single partial LOF, but did affect the embryonic brain
formation with double partial LOF (Fig. 2A). LOF was induced by
injection of antisense morpholino-modified oligonucleotides
(MOs) defined in our previous study (33), with the amount of
MO titrated so approximately 50% normal RNA remained as de-
termined by qPCR (splice-blocking MOs) or a sub-phenotypic
dose (translation blocking MOs) (Supplementary Material,
Table S1). We analysed interaction between all 162 possible
pairwise combinations of 19 genes, by assaying early brain and
ventricle morphology at 24 hours post fertilization (hpf). We
chose this assay for two reasons. First, nervous system develop-
ment is impacted by multiple signaling pathways and is sensi-
tive to perturbations (39–41). Second, radiological examinations
of people with 16p11.2 CNVs indicate changes in the volume of
certain brain regions and associated brain ventricle size (5,42–
44). However, zebrafish analyses are performed at the equiva-
lent of first trimester human embryos, and human screening for
16p11.2 deletions at these stages has not been done.
Of the 162 gene pairs tested, 16 (10%) resulted in a ventricle
phenotype after double partial LOF (Fig. 2B, Supplementary
Material, Fig. S1). A pair of genes was scored as interacting
if>50% of the double LOF embryos showed a brain morphology
phenotype after normalization. To normalize numbers, back-
ground levels of a phenotype after single gene LOF were sub-
tracted from the levels after double gene LOF. Most gene
combinations (146, 90%) did not yield any phenotype, suggesting
that interactions observed were specific. Additional controls for
MO specificity included injection with a p53 MO, since activation
of p53 has been associated with off target MO effects, and pre-
vention of a phenotype by RNA injection (45). Furthermore, other
16p11.2 homolog expression levels were not affected by double
LOF injections (Supplementary Material, Fig. S2).
We used these data to map a 16p11.2 homolog genetic inter-
action network with lines drawn between interacting genes and
scaling the font size of the gene name relative to the number of
interactions (Fig. 2C). Fourteen of nineteen genes screened were
part of this interaction map. Six of these genes emerged as
highly interactive in impacting early brain morphology: fam57ba
and kif22 with four interactions each; and asphd1, hirip3, kctd13,
and sez6l2 with three interactions each.
Because people with 16p11.2 CNV deletions exhibit multiple
symptoms and because defects in early brain morphology may in-
dicate additional nervous system involvement, we conducted a
secondary screen for four additional phenotypes: neuronal specifi-
cation using a NeuroD:GFP line, cranial motor neuron patterning us-
ing an islet1:GFP line, enteric neuron density, and muscle fiber
organization. Of the 16 gene pairs identified from our initial screen,
11 LOF pairs impacted at least one secondary screen phenotype
(Supplementary Materials, Fig. S3, Tables S2 and S3). Overall, there
was enrichment for positive interactions, showing a linkage be-
tween brain and body phenotypes. Assaying gene pairs that did
not interact with the primary screen gave no interactions for any
of the secondary screen phenotypes, indicating the strength of
brain and ventricle morphology as a first pass assay.
In sum, these initial assays identified pairs of interacting
genes in zebrafish, which were associated with phenotypes that
could be reflective of symptoms in people with 16p11.2 deletion
CNVs. None of these gene interactions has been previously de-
scribed and could not have been predicted from database analy-
sis, demonstrating the importance of functional studies for
discovery of genetic interactions.
doc2aþ/ fam57baþ/ double heterozygotes show
hyperactivity and increased seizure propensity
Mutants allow examination of gene function in older fish when
MOs would be less effective. We generated TALEN mutant lines
for some of the more interactive genes uncovered in our initial
antisense screen, including fam57ba and doc2a. Zebrafish have
two copies of the fam57b gene, and previous analysis has sup-
ported the fam57ba copy as most active (33). Mouse Fam57b en-
codes a ceramide synthase (46) and Doc2a encodes a calcium
sensor that primes vesicles for exocytosis (47,48). While there
are strong indications of synaptic defects in the literature for
some of the associated 16p11.2 CNV symptoms, particularly epi-
lepsy (49,50) and ASD (51), as well as links to metabolic defects
(52), there is little about ceramides in particular (53,54).
Therefore, this seemed an intriguing gene combination to ana-
lyse further. There are reported roles for calcium and ceramide
signaling at the synapse (55–57), and because attention deficit-
hyperactivity disorder (ADHD) and seizures are prevalent
among people with 16p11.2 deletion CNVs (2,6,8,10,58,59), we
analysed mutant zebrafish larvae for their baseline movement
level and seizure propensity.
Despite evolutionary distance, zebrafish have been a valu-
able tool for studying human epilepsies. Several assays have
been used to validate the fish as a model for human epilepsies.
Electrophysiological recordings of larval brain activity after PTZ
treatment show epileptiform discharges of brief interictal bursts
and long duration bursts similar to those seen in humans (60).
The more easily measured increased swimming speed after PTZ
treatment is directly correlated to seizure electrophysiology.
Swimming velocity can be readily measured in an automated,
high throughput system. Both swimming speed and electro-
physiological recordings show attenuated response to human
Figure 2. A subset of pairwise combinations of 16p11.2 homologs alter brain and
ventricle morphology. (A) Definition of an interacting pair. Dorsal views of 24
hpf embryos with red dye injected into the ventricles. Single gene LOFs were in-
duced to about 50% normal RNA remaining (or a sub-phenotypic dose) and
generally resembled control MO-injected embryos. If a pair of genes interacted,
then suppressing them together resulted in abnormal brain and ventricle mor-
phology. (B) Pie chart of all 162 pairwise combinations tested. (C) Map of inter-
acting pairs of genes, with the lines drawn between two genes if they interact,
and scaling the font size of the gene name according to the number of interac-
tions it has.
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anti-epileptic drugs (60,61). Zebrafish epilepsy models have led
to identification of anti-convulsant compounds for drug-
resistant Dravet syndrome (62), and of other novel anti-
convulsants (63–68). Zebrafish have also been widely used to
provide functional confirmation for gene candidates linked to
seizures in people (69–74).
Movement of seven days post fertilization (dpf), the standard
age at which these assays are conducted (60,75), wild-type and
doc2aþ/ fam57baþ/ larvae was analysed, comparing average
velocity as an output of brain activity, with and without the
seizure-inducing GABA-A antagonist pentylenetetrazol (PTZ).
Across four independent experiments, doc2aþ/ fam57baþ/ lar-
vae exhibited higher baseline movement levels as well as
increased velocity with a minimal PTZ treatment relative to
wild-type. The increased PTZ sensitivity was significant even
with normalization to account for the increased baseline move-
ment present in double heterozygotes (Fig. 3A–D). This normali-
zation was done by subtracting the baseline velocity from the
PTZ-induced velocity for each larva.
To determine the individual contributions of doc2a and
fam57ba to this interaction, we examined a spectrum of doc2a
and fam57ba genotypes, including doc2a/ and fam57ba/ sin-
gle homozygous mutants (Table 1). fam57ba/ mutants dis-
played higher baseline movement and PTZ sensitivity, but not
to the same degree as double heterozygote doc2aþ/ fam57baþ/
larvae (Fig. 3E–H). The double heterozygotes showed signifi-
cantly higher activity than wild-type after a minimal 0.3 mM
PTZ dose, which is far below the established dosing range of 2.5
to 25 mM required to induce seizures in wild-type fish (60,76).
In contrast, fam57ba/ mutants needed 5 mM PTZ to show a
nominally significant increase in velocity compared to wild-
type. Single heterozygous doc2aþ/ and fam57baþ/ fish did not
show differences in baseline activity or 0.3 mM PTZ sensitivity
compared to wild-type, indicating an interaction in the double
heterozygote (Fig. 3I–P). doc2a/ mutants alone did not exhibit
changes in baseline movement or seizure susceptibility relative
to wild-type at 0.3 mM (data not shown) or 5 mM PTZ (Fig. 3Q–T).
Single heterozygotes were also tested at the higher 5 mM PTZ
dose, but no significant differences were observed (data not
shown). All genotypes tested except for fam57baþ/ exhibited a
significant (P< 0.0001) response to PTZ treatment at the tested
doses indicated in Figure 3.
In order to confirm the specificity of the seizure response in our
lines, we treated the larvae with human anti-epileptic drugs
(AEDs). We also examined for musculature and caudal motoneu-
ron differences. We used valproic acid (VPA), the most widely pre-
scribed AED worldwide, and a broad spectrum drug that is effective
against all seizure types (77), and carbamazepine, another first
choice AED for partial epilepsies (78). Both drugs have been previ-
ously assessed in zebrafish as inhibiting PTZ-induced epileptiform
discharges and increased swimming (60,61). We found that VPA
treatment before PTZ treatment decreased average swimming ve-
locity to around 28% of velocity after PTZ alone in wild-type, and
22% in doc2aþ/ fam57baþ/ and fam57ba/ larvae. Carbamazepine
treatment suppressed movement to about 42% of the PTZ baseline
in wild-type, 35% in doc2aþ/ fam57baþ/, and 53% in fam57ba/
larvae (Supplementary Material, Fig. S4). Immunohistochemical
analysis of muscle fibers and primary caudal motoneurons ex-
hibited no obvious differences between wild-type, doc2aþ/
fam57baþ/, and fam57ba/, indicating that these would not con-
tribute to movement differences (Supplementary Material, Fig. S5).
These data demonstrate a robust genetic interaction be-
tween the fam57ba and doc2a genes resulting in hyperactivity
and seizure susceptibility.
doc2aþ/ fam57baþ/ heterozygotes and fam57ba/
mutants show increased body and head size
Since large body size, macrocephaly and obesity are significant
symptoms among people with the 16p11.2 deletion, we next ex-
amined body size and head size in doc2aþ/ fam57baþ/ larvae
and other doc2a and fam57ba genotypes. In people with the
16p11.2 deletion, incidence of obesity increases with age, be-
coming significantly different from non-carriers by 3.5 years.
There is also a correlated increase in pre-pubertal height above
the population average, but only in obese 16p11.2 CNV deletion
carriers. The occurrence of increased head circumference is also
positively correlated with age and with obesity (10). With these
considerations, head and body size of fish about halfway
through the larval period (12 dpf) were assayed to assess a later
developmental time point, perhaps more relevant to onset of
human phenotypes.
A significant increase in body length was found in doc2aþ/
fam57baþ/ larvae at 12 dpf (Fig. 4A–C). To analyse lipid content,
larvae were stained with the lipid-binding dye Oil Red O (ORO),
and the ORO was then extracted and quantified. While ORO
concentrations were significantly elevated in doc2aþ/
fam57baþ/ double heterozygotes (Fig. 4D), this difference was
not seen after accounting for body length (Fig. 4E). In analysis of
additional genotypes, we found that fam57ba/ larvae dis-
played a much greater increase in body length versus wild-type
(Fig. 4F–H). These fish also showed a significant increase in lipid
content, even after normalizing to body length (Fig. 4I–J). Since
doc2aþ/, fam57baþ/, and doc2a/ larvae did not show changes
in body size or lipid content (Fig. 4K–Y), we conclude that with
regard to body size, there is an interaction in the double hetero-
zygote for body size but not normalized lipid content.
To assess head size, various measurements of mutants were
made relative to wild-type larvae at 12 dpf (Fig. 5). doc2aþ/
fam57baþ/ fish showed slight increases in a subset of the di-
mensions, while fam57ba/ larvae showed significant changes
in all dimensions measured, indicating that losing both copies
of fam57ba has the more powerful effect on head size as well as
body size. Single heterozygous doc2aþ/ and fam57baþ/ larvae
did not show changes in head size in any dimension, while
doc2a/ larvae showed a decrease in inter-eye width and an in-
crease in two other dimensions (Fig. 5). If increased head di-
mensions are normalized by dividing by the body length of
doc2aþ/ fam57baþ/ and fam57ba/ larvae, then no significant
differences from wild-type are observed (not shown). Therefore,
we predict DOC2A and in particular FAM57B contribute to gen-
eral growth patterns, rather than specifically to head size, al-
though species differences may play into the results.
These data demonstrate that doc2aþ/ fam57baþ/ heterozygotes
and fam57ba/ mutants show increased head size, body size, and
lipid content – phenotypes that are consistent with obesity.
Discussion
A major challenge in human genetics is the definition of how
multigenic copy number variant regions connect to multiple as-
sociated symptoms. Deletion of the 16p11.2 CNV is paradig-
matic of this challenge, presenting a global burden for four
million affected people. We used the tractable zebrafish system
and a functional screen to uncover genotype/phenotype con-
nections amongst 16p11.2 homologs, reaching three major con-
clusions. 1) A subset of 16p11.2 genes interact after partial loss
of function and define a functional network, 2) the doc2a and
fam57ba genes interact to regulate hyperactivity and seizure
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propensity, and 3) doc2a and fam57ba genes also interact to con-
trol head and body size, with greater contribution from fam57ba.
These conclusions add new understanding to the mechanism
underlying 16p11.2 deletion phenotypes, and further suggest
previously undescribed correlations between brain and body
health.
Gene interactions among the 16p11.2 interval do not con-
verge on functional networks predicted by gene-set enrichment
Figure 3. doc2a and fam57ba interact to increase hyperactivity and seizure propensity. (A,B) Movement traces of individual 7 dpf larvae in wells of a 96-well plate before
and after addition of the seizure-inducing drug PTZ (dose is 0.3 mM for top and bottom panels in B, J, and N and 5 mM for top and bottom panels in F and R). Traces
show wild-type larval paths during a 10-min recording. Top panels are wild-type, bottom panels are doc2aþ/ fam57baþ/ double heterozygous larvae, which show in-
creased movement compared to wild-type both with and without PTZ. (C) Average velocity of baseline movement (no PTZ) shows the increased movement of doc2aþ/
fam57baþ/ larvae (yellow bar) compared to wild-type controls (blue bar), with n’s shown above bars. (D) After PTZ addition, doc2aþ/ fam57baþ/ show increased veloc-
ity compared to wild-type, even after taking baseline movement differences into account by subtracting the baseline velocity from the velocity with PTZ for each larva.
(E,F) Movement traces before and after 5 mM PTZ addition for wild-type and fam57ba/ larvae. (G) Average velocity of baseline swimming is significantly higher in
fam57ba/ (purple bar) compared to wild-type larvae (blue bar). (H) After 5 mM PTZ addition, fam57ba/ larvae show significantly increased velocity, even after sub-
tracting the increased baseline velocity for each individual fish. (I–P) Analysis of fam57baþ/ (green bars) and doc2aþ/ (orange bars) single heterozygotes indicate an in-
teraction for doc2aþ/ fam57baþ/ larvae double heterozygous larvae because no significant differences in baseline activity or PTZ response are observed in single
heterozygotes. (Q–R) doc2a/ larvae do not show increased velocity before or after 5 mM PTZ addition (pink bars). *P<0.05, ***P<0.001.
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analysis (79). Furthermore, no evidence for physical interactions
between 16p11.2 genes has been found (80). These findings im-
ply indirect mechanisms of gene interaction, which could only
be uncovered by functional assays. Genetic interaction data do
not indicate mechanism, but are invaluable in focusing subse-
quent molecular or cellular assays.
The subset of highly interactive 16p11.2 zebrafish homologs
that our pairwise assays reveal have diverse predicted func-
tions, and include asphd1, fam57ba, hirip3, kctd13, kif22 and
sez6l2 (Table 2). The initial hypothesis that each pair of genes
would be sufficient to regulate a specific 16p11.2 phenotype
may be too simple, as suggested by the network of interactions
uncovered that affect a single phenotype. Rather, each 16p11.2
deletion symptom may depend on haploinsufficiency of multi-
ple genes (Fig. 1). It is possible that even if multiple 16p11.2
genes regulate each symptom, these converge functionally on a
few common biochemical or cell biological targets.
The interaction of doc2a and fam57ba in genetic mutants sug-
gests a mechanism by which brain activity is regulated.
Although both genes are expressed predominantly in the head
of larval zebrafish (Supplementary Material, Fig. S6) and are ap-
parently co-expressed in the adult mouse brain (81) and the pre-
natal human brain (82), it is unclear whether they function in
the same cells. The Doc2a gene encodes a calcium sensor that
interacts with the docking machinery to prime vesicles for exo-
cytosis (47,48,83), including at the synapse (57). Mutations in
other synaptic vesicle docking components are associated with
ADHD and epilepsy (72,84,85).
Fam57b has a Tram-Lag1-Cln8 (TLC) domain associated with
ceramide synthases (86), and is capable of ceramide synthesis in
vitro (46). Based on this ceramide synthase activity, we predict
that there is a change in the ceramide cohort in fam57ba mutant
fish, and possibly in people with 16p11.2 CNVs. Serum levels of
particular sphingomyelins, a ceramide derivative, have been
shown to be decreased in people with ADHD (87). Mice treated
with fumonisin B1, a general ceramide synthase inhibitor, are
sensitized to PTZ-induced seizures (88), and mutations in two
ceramide synthase genes in humans are associated with pro-
gressive myoclonus epilepsy (54,89).
Dysregulated ceramides could interact with DOC2A to im-
pact synaptic signaling in several ways (Fig. 6). Ceramides
are critical structural components of cell membranes and dysre-
gulation could affect vesicle fusion and endocytic recycling. In
cell culture, ceramide application was found to enhance exocy-
tosis (90). Various ceramide derivatives interact with compo-
nents of the SNARE vesicular docking complex (91,92) and
recruit Munc13 (93) – the binding partner of DOC2A (47,48) – and
enhance intracellular calcium flow (94), which could help acti-
vate DOC2A. These findings point to future analyses addressing
the molecular pathways by which these genes control synaptic
activity and their cellular targets.
No 16p11.2 gene has previously been linked to the increased
body size observed in people with deletion of one 16p11.2 copy.
The longer body length we observe in doc2aþ/ fam57baþ/ dou-
ble heterozygotes is consistent with increased height in people
with 16p11.2 deletion CNVs. While single heterozygote and dou-
ble heterozygote genetic data support the necessity of doc2a in
the haploinsufficient interaction, the strong phenotype ob-
served in fam57ba/ single mutants suggests that this is the
pivotal gene driving body size phenotypes. In our studies,
fam57ba showed a clear function in regulating lipid content,
suggesting that this gene may promote normal amounts of fat.
While obesity is generally defined as having too much body fat,
a body mass index (BMI) of30 is used as the clinical indicator
of obesity. Because there is no universally accepted value of an
obese zebrafish BMI value in larvae and because weighing larvae
at this stage is not consistently accurate, we analysed the total
lipid content in relation to body length, and by these criteria,
fam5ba/ fish are obese. Interaction of FAM57B with another
16p11.2 gene(s) such as DOC2A may modulate body size.
Consistent with this suggestion, manipulating other synaptic
vesicle docking components like DOC2A has been associated
with metabolic changes contributing to obesity, presumably
from disruption of hormonal and/or neurotransmitter release
dynamics (95,96). While fam57ba/ mutants also had signifi-
cantly increased lipid content, even after normalizing to body
size, doc2aþ/ fam57baþ/ double heterozygotes did not, imply-
ing that in the human hemizygous condition, FAM57B could be
interacting with another as yet to be identified 16p11.2 gene(s)
to regulate lipid content.
Macrocephaly is generally defined as an absolute measure
and does not take body size into account. Disproportionate
macrocephaly refers to an increase in head size relative to the
body length (97). In people with 16p11.2 CNV deletion, dispro-
portionate macrocephaly is observed, as head circumference is
elevated even after taking body mass index (BMI) into account
(10). In zebrafish, doc2aþ/ fam57baþ/ and fam57ba/ larvae
only show indications of absolute macrocephaly, indicating so-
matic overgrowth. Together, the increased body length, lipid
content, and head size indicate that doc2a and fam57ba impact
growth patterns and overall size, consistent with phenotypes
seen in people with 16p11.2 deletion (10).
Since both doc2a and fam57ba are predominantly expressed
in the head (Supplementary Material, Fig. S6), we hypothesize
that their effects on body size may be exerted through changes
in the brain. For example, signaling deficits, arising from poten-
tial ceramide and synaptic vesicle docking mechanisms dis-
cussed above, in neural circuits regulating appetite could
contribute to differences in body size. This is in contrast to the
suggestion that mouse Fam57b acts directly in cultured adipo-
cytes, where overexpression and exogenous ceramide applica-
tion inhibited lipid accumulation, and knockdown resulted in
increased lipids (46). However, previous work in zebrafish has
shown that adipocytes are only starting to appear at 12 dpf, and
do not fully differentiate in larvae until 17 dpf (98), five days af-
ter our size measurements were done. This does not preclude a
Table 1. fam57ba and doc2a genetic mutants affect brain and body
size phenotypes. doc2aþ/ fam57baþ/ has a stronger effect on in-
creasing hyperactivity and seizures compared to wild-type, while
fam57ba/ has a stronger effect on increasing body size, lipid con-
tent, and head size compared to wild-type. Single heterozygotes for
each gene as well as doc2a homozygotes do not affect any of these
phenotypes, although doc2a/ larvae have decreased head sizes in
one dimension, and increased in other dimensions. This indicates a
genuine interaction between doc2a and fam57ba to increase hyperac-
tivity and seizures. Two arrows indicate a stronger effect relative to
wild-type compared to a single arrow. A dash indicates no signifi-
cant differences from wild-type.
docþ/famþ/ fam57ba/ fam57baþ/ doc2aþ/ doc2a/
Hyperactivity "" " – – –
Seizures "" " – – –
Body size " "" – – –
Lipid content " "" – – –
Head Size " "" – – –
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possible contribution from premature adipocyte differentiation
in fam57ba/ mutants, but we did not observe significant
differences in white adipose tissue depots at 12 dpf (data not
shown).
The effects of mutating fam57ba and doc2a in zebrafish are
more similar to increased body and head size in people with
16p11.2 deletions than phenotypes seen in mouse models.
Instead, mouse 16p11.2 deletion models exhibit reduced body
and head size as well as decreased adiposity and do not recapit-
ulate this human phenotype (30–32). Mouse models do recapitu-
late other aspects of human symptoms, including hyperactivity,
impaired learning, and social deficits (30–32,99), illustrating the
utility of using multiple animal models to address human gene
function.
Our results indicate for the first time that FAM57B functions
in both brain and body health, through interaction with DOC2A
and perhaps together with other, as yet unidentified genes
(summarized in Fig. 6). Together, these data suggest that in peo-
ple with 16p11.2 deletions, ceramide dysregulation and altered
exocyotosis may be mechanisms underlying seizures and obe-
sity. The identification of a potential lipid mechanism underly-
ing pathology suggests a role for metabolic regulation of the
16p11.2-related phenotypes addressed. Because we focused on
this single interaction for further analysis, there is nothing to
Figure 4. Body size and lipid amounts are affected by doc2a and fam57ba. A representative experiment is shown from the 5 conducted. (A,B) 12 dpf larvae stained with
Oil Red O (ORO) are shown for wild-type and doc2aþ/ fam57baþ/. (C) A significant increase in body length as measured from the tip of the nose to the end of the tail is
found for doc2aþ/ fam57baþ/ larvae (n¼19) compared to wild-type (n¼19). (D) ORO was extracted back out of the stained larvae and quantified, showing a significant
increase in the concentration of lipids in the double heterozygotes (yellow bar) compared to wild-type (blue bar). (E) After accounting for length, there is no longer a sig-
nificant increase in ORO concentration in doc2aþ/ fam57baþ/ larvae. (F,G) Wild-type and fam57ba/ larvae stained with ORO. (H) A significant increase in body length
was found comparing fam57ba/ larvae (n¼30) to wild-type (n¼ 30). (I) ORO quantification showed a significant increase in the concentration of lipids for fam57ba/
homozygotes (purple bar) compared to wild-type (blue bar). (J) When accounting for length, ORO concentration is still significantly elevated in fam57ba/ fish. (K–Y) No
significant changes in size or ORO concentration were observed for fam57baþ/ (n¼ 29), doc2aþ/ (n¼26), and doc2a/ (n¼36) larvae compared to their respective wild-
type controls. **P<0.01, ***P<0.001, ****P< 0.0001. Scale bar¼500 mm.
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rule out that other 16p11.2 genes also contribute to seizure pro-
pensity and body size, as well as other phenotypes. Future di-
rections include molecular analysis of fam57ba and doc2a
interaction, assessment of whether function of these genes is
dysregulated in human 16p11.2 deletion cells, and exploring in-
teractions of additional 16p11.2 homologs with doc2a and/or
fam57ba related phenotypes.
Materials and Methods
Fish lines and maintenance
Adult zebrafish of the wild-type AB strain were maintained at
28˚C on 12h/12h light/dark cycle. Embryos were obtained from
natural spawnings and staged as previously described by
Kimmel et al. (1995). The transgenic lines used, islet1:GFP and
NeuroD:GFP, have been previously characterized (100,101).
Due to the polygenic nature of sex determination and timing of
gonadal development in zebrafish (102,103), we are unable to
determine the sexes of the embryos and larvae for our
Figure 5. doc2a and fam57ba affect head size. A representative experiment from 4 experiments conducted is shown for each genotype. (A) Dorsal schematic of 12 dpf lar-
val head, with panel letters indicating lines for the 4 measurements taken. (B–E) Fold-change relative to respective wild-type controls (blue bars) is shown for doc2aþ/
fam57baþ/ (yellow bars, n¼19), fam57ba/ (purple bars, n¼19), fam57baþ/ (green bars, n¼29), doc2aþ/ (orange bars, n¼26), and doc2a/ (pink bars, n¼36) larvae for
inter-eye width, dorsal head length (D), hindbrain width, and forebrain width. (F) Lateral schematic of 12 dpf larval head, with panel letters indicating the four mea-
surements taken. (G–J) Fold-change relative to respective wild-type controls for each genotype as described above for lateral head length (L), head height, eye width
and eye height. (K,L) Live dorsal and lateral images of representative larvae for each genotype. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Scale bar¼ 100 lm.
Table 2. Diverse predicted functions for most interactive 16p11.2
genes. Little is known about ASPHD1 function, although it contains
an aspartate beta-hydroxylase domain, and aspartate beta-hydroxy-
lase is important for regulating calcium homeostasis (112). FAM57B
is a ceramide synthase that regulates adipogenesis in mouse tissue
culture cells (46). HIRIP3 may be part of a complex involved in chro-
matin and histone metabolism (113). KCTD13 encodes a ubiquitin li-
gase adaptor (114) that is reported to have reciprocal effects on
zebrafish head size with gain- and loss-of-function (35). KIF22 is a
kinesin-like protein that links chromosomes to the mitotic spindle
(115,116), and is necessary for proper embryonic chromosome segre-
gation (118) and synaptic development (34). SEZ6L2 is a seizure-re-
lated protein that modulates neurite outgrowth (117).
Gene Symbol Functions References
ASPHD1 Regulates calcium homeostasis? (112)
FAM57B Ceramide synthase (46)
HIRIP3 Chromatin and histone metabolism (113)
KCTD13 Ubiquitin ligase adaptor (114)
KIF22 Links chromosomes to mitotic spindle (115,116)
SEZ6L2 Modulates neurite outgrowth (117)
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assays. However, because our assays utilized large numbers
of embryos and larvae, both sexes should be adequately
represented.
Antisense morpholino-modified oligonucleotide
design and use
We chose to focus on only those 16p11.2 zebrafish homologs that
gave a brain phenotype in our single gene study. This means we
did not test prrt2 or tbx24 or the b copies for aldoa, fam57b, and
ppp4c. The antisense morpholino-modified oligonucleotides (MOs)
utilized were the same as our previous study (sequences and spe-
cificity assays in (33)). Concentrations for splice-blocking MOs that
resulted in approximately 50% normal RNA remaining at 24 hpf
are in Supplementary Material, Table S1. These doses were deter-
mined by qPCR using the same primers as previously described
(33), except for hirip3 primers, which were F: 5’-GTTGTG
GCTCAACTGCAGAA and R: 5’-GCACTGAGCGACTCTCTTCC. For
the start site MOs, doses that did not result in a phenotype when
injected alone were used (Supplementary Material, Table S1).
Because aldoaa and kif22 LOF give a phenotype at 50% LOF, non-
phenotypic doses at 25% LOF were used in interaction assays. To
control for MO load in testing interactions, single MO injections
were balanced with the same amount of control MO as would be
used for the test partner MO. For the control condition, the same
amount of control MO was used as the combined amounts in the
double LOF condition.
Morphological assays
Brain ventricle morphology was evaluated at 24 hpf. Texas Red
dextran (Sigma) was injected into ventricle space as done previ-
ously (104). Dye injection does not affect morphology (105).
Neuronal specification and cranial motor neuron patterning
were analysed at 2 dpf using transgenic lines. Embryos were
scored in 2–4 independent experiments, with the com-
bined number of embryos scored across experiments shown in
the figures.
Microscopy
Bright-field and fluorescent images were captured on a Zeiss
Stereo Discovery V8 microscope with an AxioCam MRc digital
camera using ZEN software (Zeiss). Confocal imaging was per-
formed on an inverted Zeiss LSM710 laser-scanning microscope
with a 25X (0.8 NA) LD LCI Plan Apochromat oil-immersion
objective.
Immunohistochemistry
Embryos and larvae were fixed in 4% PFA. Anti-HuC/D monoclo-
nal antibody (Invitrogen) was used at 1:500, znp1 (anti-SYT2,
Abcam) monoclonal antibody was used at 1:200, and Alexa
Fluor 488 secondary antibody (Jackson) was used at 1:400. Alexa
Fluor 635 phalloidin (Invitrogen) was used at 1:40. Cell counting
was done in Imaris (Bitplane) with manual threshold
adjustment.
TALEN generation and identification of TALEN mutants
Target sites for TALENs were identified using Mojo Hand (106)
and TALE-NT 2.0 (107). All sites chosen had a restriction enzyme
site at the cut site to be used for genotyping (Supplementary
Material, Table S4). TALENs were cloned and injected into one-
cell zebrafish embryos as previously described (108,109). F0 fish
with high germline transmission rates were identified by loss of
restriction site, sequenced, and outcrossed. The resulting het-
erozygous F1 fish were in-crossed if they carried the same mu-
tation to generate wild-type, heterozygous, and mutant
siblings. These F2 fish were bred to generate embryos and larvae
used in the experiments described below.
Seizure assays
Wild-type and doc2aþ/ fam57ba þ/ double heterozygous cousin
embryos were obtained from separate crosses of sibling wild-
type and single homozygous mutant fish, respectively. Single
heterozygous fish were generated by crossing homozygous to
wild-type fish. At 7 dpf, larvae were pipetted into 96-well plates
in 200 ml E3 media, allowed to acclimate to the plate for 15 min,
and then moved to the Noldus Daniovision for another 10 min
habituation period. Baseline activity was then recorded for
10 min. Following this, 100 ml E3 was removed from each well,
and replaced with 100 ml of varying concentrations of PTZ to test
a range of doses. Plates were immediately placed back on the
Daniovision system for a 10-min habituation period, followed
by another 10- min recording. Average velocity was calculated
using the Ethovision XT 11 software from Noldus. The numbers
shown in the figures are combined from 2 to 5 independent ex-
periments. Even though there may not necessarily be a correla-
tion between baseline movement and velocity after PTZ
addition, we still accounted for this possibility by normalization
via subtracting the baseline velocity from the PTZ-induced ve-
locity for each larva.
Figure 6. Hypothesis: FAM57B and DOC2A are critical regulators of brain and
body health. Loss of a single copy of both FAM57B and DOC2A genes may lead to
increased body size and seizures through the brain, where both genes are pre-
dominantly expressed. Inset of pre-synaptic terminal: Ceramides potentially in-
teract with DOC2A to impact the vesicular release. Ceramides and ceramide
derivatives represented by green squares (in cell and vesicular membranes) and
triangles. Docking and release of neurotransmitters (gray circles) from synaptic
vesicles may be influenced by ceramides and DOC2A in several ways. The cer-
amide derivative sphingosine promotes vesicular fusion via activation of the
SNARE component SYNAPTOBREVIN (92). Sphingosine also influences another
SNARE component, SYNTAXIN, to enhance its interaction with MUNC18, which
promotes an active conformation of SYNTAXIN (91). Sphingosine-1-phosphate
may contribute to neurotransmitter release via recruitment of MUNC13 (93), the
vesicle docking component that is activated by DOC2A binding after calcium in-
flux (47,48). Ceramide-1-phosphate has been shown to enhance intracellular cal-
cium concentrations by acting on voltage-gated calcium channels (94).
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Anti-epileptic drug treatments
Human anti-epileptic drugs were added to larvae for 15 min be-
fore PTZ addition and seizures were assayed as above. Valproic
acid (Sigma) was used at 3 mM and carbamazepine (Sigma) was
used at 100 mM.
Oil red O staining and quantification
To control for variable growth rates, bowl larval density was
checked daily to ensure equal numbers of wild-type and test ge-
notype larvae within experiments. Larvae were fixed at 12 dpf
in 4% PFA and washed in PBS. Pigment was bleached with 1%
KOH/3% H2O2 solution. The 0.5% stock Oil Red O (ORO, Sigma)
solution was made in isopropanol. Immediately before use, a
working 0.3% solution was made with dH2O, allowed to stand
for 10 min after mixing, and then filtered. Larvae were incubated
in the fresh working solution for 30 min to 2 h, rinsed quickly
twice in 60% isopropanol, and rinsed again in PBS (110,111).
To quantify ORO amount, ORO was extracted back out of 15–
25 stained larvae per genotype by soaking 2–4 fish in 300 ml iso-
propanol for at least 60 min with occasional agitation until lar-
vae appeared white in appearance. The supernatant from these
6–8 pools per genotype was removed, split in triplicate, and ab-
sorbance was measured at 492 nm (averaged from 10 readings
per well). Average concentration was calculated per larva by
comparison to a standard curve analysed on the same plate.
Statistical analysis
Exact binomial tests were used for statistical analysis compar-
ing qualitative phenotypes. Unpaired nonparametric t-tests
were used for statistical analysis comparing quantitative phe-
notypes. Unless noted otherwise, error bars on bar graphs re-
flect standard error, while error bars on scatter plots show
standard deviation.
Supplementary Material
Supplementary Material is available at HMG online.
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